Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van Hout

Showing results (31-40 of 126) with videos related to

Pageof 13
Sort By:
Pharmacoeconomics|March 12, 2003
The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximationBen A van Hout, Dennis D Gagnon, Pauline McNulty, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 9, 2004
[Sepsis, a complicated syndrome with major medical and social consequences]J Bakker, M Levi, B A van Hout, et al.
BMJ Open|June 11, 2015
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the diseaseStephanie Stephens, Marc F Botteman, Mary A Cifaldi, et al.
European Heart Journal|May 23, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Journal of Medical Genetics|October 10, 1997
Cost effectiveness of DNA diagnosis for four monogenic diseasesA A van der Riet, B A van Hout, F F Rutten
Kidney International. Supplement|January 4, 1998
Economic evaluation of benazepril in chronic renal insufficiencyB A van Hout, G P Simeon, J McDonnell, et al.
Journal of Internal Medicine|August 18, 2000
Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch womenC J Moerman, B A Van Hout, L Bonneux, et al.
Pharmacoeconomics|April 8, 1993
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic modelB A van Hout, G Wielink, G J Bonsel, et al.
American Heart Journal|April 16, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 17, 1996
[Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control]C E de Laet, B A van Hout, A Hofman, et al.
Pageof 13

Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Pharmacoeconomics|March 12, 2003
The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximationBen A van Hout, Dennis D Gagnon, Pauline McNulty, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 9, 2004
[Sepsis, a complicated syndrome with major medical and social consequences]J Bakker, M Levi, B A van Hout, et al.
BMJ Open|June 11, 2015
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the diseaseStephanie Stephens, Marc F Botteman, Mary A Cifaldi, et al.
European Heart Journal|May 23, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Journal of Medical Genetics|October 10, 1997
Cost effectiveness of DNA diagnosis for four monogenic diseasesA A van der Riet, B A van Hout, F F Rutten
Kidney International. Supplement|January 4, 1998
Economic evaluation of benazepril in chronic renal insufficiencyB A van Hout, G P Simeon, J McDonnell, et al.
Journal of Internal Medicine|August 18, 2000
Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch womenC J Moerman, B A Van Hout, L Bonneux, et al.
Pharmacoeconomics|April 8, 1993
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic modelB A van Hout, G Wielink, G J Bonsel, et al.
American Heart Journal|April 16, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 17, 1996
[Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control]C E de Laet, B A van Hout, A Hofman, et al.
Pageof 13